Ellevest Inc’s Standard BioTools LAB Stock Holding History

Ellevest Inc’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30	Closed	–	–	1737
2022 Q2	$0	Sell	30 -8	-21%	-$20	﹤0.01%	1541
2022 Q1	$0	Buy	+38	New	+$131	﹤0.01%	1526
2021 Q2	–	Sell	-10	Closed	–	–	1346
2021 Q1	$0	Hold	10	–	–	﹤0.01%	1307
2020 Q4	$0	Buy	+10	New	+$66	﹤0.01%	1276

Other funds holding LAB

ICM

Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JCP

Jennifer C. Price $75.5M AUM 6.25% 1-Year Est. Return

Ellevest Inc's LAB Position: Q3 2022 in Review

Ellevest Inc sold out of Standard BioTools (LAB) in Q3 2022, closing a stake of 30 shares.

Ellevest Inc first reported a position in LAB in Q4 2020 and held it in 4 quarters. The position peaked at $0 in Q2 2022. 65 funds tracked by Wall St. Rank hold LAB as of Q3 2022.

Ellevest Inc reported no remaining Standard BioTools position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 30 Standard BioTools shares in Q3 2022.
Ellevest Inc first reported a position in Standard BioTools in Q4 2020 and held it in 4 quarters.
Ellevest Inc's Standard BioTools position peaked at $0 in Q2 2022.
65 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.